New diabetes drug tested in kids: how long does it stay in the body?

NCT ID NCT06362265

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a new medicine, LY3209590, is processed in the bodies of 15 children with type 2 diabetes. Each child received one dose, and researchers measured the drug levels in their blood over time. The goal was to understand how the drug is absorbed and removed, not to treat the disease. The study lasted about 100 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Centricity Research Columbus Endocrinology

Columbus, Georgia, 31904, United States
Children's Healthcare of Atlanta - Center for Advanced Pediatrics

Atlanta, Georgia, 30329, United States
Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States
Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States
Joslin Diabetes Center

Boston, Massachusetts, 02215, United States
Lifedoc Research - Lenox Park Drive

Memphis, Tennessee, 38115, United States
NYU Langone

New York, New York, 10016, United States
UBMD Pediatrics

Buffalo, New York, 14203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.